[go: up one dir, main page]

CN111051347A - Tigit抗体、其抗原结合片段及医药用途 - Google Patents

Tigit抗体、其抗原结合片段及医药用途 Download PDF

Info

Publication number
CN111051347A
CN111051347A CN201880058441.3A CN201880058441A CN111051347A CN 111051347 A CN111051347 A CN 111051347A CN 201880058441 A CN201880058441 A CN 201880058441A CN 111051347 A CN111051347 A CN 111051347A
Authority
CN
China
Prior art keywords
antibody
tigit
human
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880058441.3A
Other languages
English (en)
Other versions
CN111051347B (zh
Inventor
付雅媛
曹卓晓
胡齐悦
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111051347A publication Critical patent/CN111051347A/zh
Application granted granted Critical
Publication of CN111051347B publication Critical patent/CN111051347B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种TIGIT抗体、其抗原结合片段及医药用途。进一步地，还涉及包含所述TIGIT抗体CDR区的鼠源抗体、嵌合抗体、人源化抗体，以及包含TIGIT抗体及其抗原结合片段的药物组合物，以及其作为药物的用途。特别地，还涉及一种人源化的TIGIT抗体在制备用于治疗TIGIT相关的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201880058441.3A 2017-09-29 2018-09-28 Tigit抗体、其抗原结合片段及医药用途 Active CN111051347B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710908565 2017-09-29
CN2017109085653 2017-09-29
PCT/CN2018/108246 WO2019062832A1 (zh) 2017-09-29 2018-09-28 Tigit抗体、其抗原结合片段及医药用途

Publications (2)

Publication Number Publication Date
CN111051347A true CN111051347A (zh) 2020-04-21
CN111051347B CN111051347B (zh) 2021-12-21

Family

ID=65900702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880058441.3A Active CN111051347B (zh) 2017-09-29 2018-09-28 Tigit抗体、其抗原结合片段及医药用途

Country Status (6)

Country Link
US (1) US11512129B2 (zh)
EP (1) EP3689909A4 (zh)
JP (1) JP7317272B2 (zh)
CN (1) CN111051347B (zh)
TW (1) TWI803523B (zh)
WO (1) WO2019062832A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563470A (zh) * 2020-04-29 2021-10-29 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CN116003625A (zh) * 2021-08-20 2023-04-25 中山康方生物医药有限公司 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
CN118451107A (zh) * 2021-12-17 2024-08-06 上海九葫禾生物科技有限公司 Tigit抗体及其用途

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
TWI816729B (zh) 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
SG11202004521QA (en) * 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
AU2020314129A1 (en) * 2019-07-15 2022-02-24 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibodies and application thereof
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
EP4119162A4 (en) 2020-03-13 2023-08-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PVRIG-BINDING PROTEIN AND ITS MEDICAL USES
WO2021216372A1 (en) * 2020-04-23 2021-10-28 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
US20230258645A1 (en) 2020-05-07 2023-08-17 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
AU2021293507A1 (en) 2020-06-18 2023-02-02 F. Hoffmann-La Roche Ag Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
TWI815220B (zh) * 2020-11-23 2023-09-11 大陸商廣東菲鵬制藥股份有限公司 抗tigit抗體或其抗原結合片段及其生產方法與應用，以及包含其的核酸、載體、細胞、藥物組合物及試劑盒
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
EP4320155A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
BR112023022367A2 (pt) * 2021-05-04 2024-02-20 Agenus Inc Anticorpos anti-tigit e métodos de uso dos mesmos
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
WO2022237882A1 (zh) 2021-05-14 2022-11-17 江苏恒瑞医药股份有限公司 一种抗原结合分子
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
EP4403574A4 (en) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd PD-1-Specific Protein and Its Pharmaceutical Use
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CN117858903A (zh) 2021-09-15 2024-04-09 江苏恒瑞医药股份有限公司 一种含抗pvrig/tigit双特异性抗体的药物组合物
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
CN114480298B (zh) * 2022-04-14 2022-06-24 迈杰转化医学研究(苏州)有限公司 一株分泌抗tigit单克隆抗体的杂交瘤细胞株及其应用
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024188331A1 (zh) 2023-03-15 2024-09-19 上海迈晋生物医药科技有限公司 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2025002151A1 (zh) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
WO2025061119A1 (en) * 2023-09-21 2025-03-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-tigit antibodies and uses thereof
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
CN119285777A (zh) * 2023-10-11 2025-01-10 首都医科大学附属北京胸科医院 抗人tigit单克隆抗体tigit-m013或其功能性片段及其应用
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073644A (zh) * 2012-12-31 2013-05-01 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
WO2017037707A1 (en) * 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017059095A1 (en) * 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
AU2021293507A1 (en) * 2020-06-18 2023-02-02 F. Hoffmann-La Roche Ag Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073644A (zh) * 2012-12-31 2013-05-01 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
WO2017037707A1 (en) * 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017059095A1 (en) * 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOZANO,E 等: "The TIGIT/CD226 Axis Regulates Human T Cell Function", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563470A (zh) * 2020-04-29 2021-10-29 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CN116003625A (zh) * 2021-08-20 2023-04-25 中山康方生物医药有限公司 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
CN118451107A (zh) * 2021-12-17 2024-08-06 上海九葫禾生物科技有限公司 Tigit抗体及其用途
CN118451107B (zh) * 2021-12-17 2025-06-17 上海九葫禾生物科技有限公司 Tigit抗体及其用途
CN120757647A (zh) * 2021-12-17 2025-10-10 上海九葫禾生物科技有限公司 Tigit抗体及其用途
CN120757648A (zh) * 2021-12-17 2025-10-10 上海九葫禾生物科技有限公司 Tigit抗体及其用途

Also Published As

Publication number Publication date
TW201915026A (zh) 2019-04-16
US20200255516A1 (en) 2020-08-13
TWI803523B (zh) 2023-06-01
EP3689909A4 (en) 2021-12-29
JP7317272B2 (ja) 2023-07-31
US11512129B2 (en) 2022-11-29
WO2019062832A1 (zh) 2019-04-04
EP3689909A1 (en) 2020-08-05
CN111051347B (zh) 2021-12-21
JP2020537509A (ja) 2020-12-24

Similar Documents

Publication Publication Date Title
CN111051347B (zh) Tigit抗体、其抗原结合片段及医药用途
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
KR102497259B1 (ko) Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN109983032B (zh) Tim-3抗体、其抗原结合片段及医药用途
CN111051343A (zh) Il-6r抗体、其抗原结合片段及医药用途
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN113840836A (zh) 抗结缔组织生长因子抗体及其应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
WO2024255683A1 (zh) 抗bdca2抗体
HK40051455A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
HK40045560A (zh) 抗cd73抗体、其抗原结合片段及应用
HK40009319B (zh) B7-h3抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant